331 related articles for article (PubMed ID: 33517310)
1. Serum Soluble Interleukin-2 Receptor as a Potential Biomarker for Immune-related Adverse Events.
Takai R; Funakoshi Y; Suto H; Nagatani Y; Imamura Y; Toyoda M; Yakushijin K; Kiyota N; Harada KI; Yamashita K; Kakeji Y; Minami H
Anticancer Res; 2021 Feb; 41(2):1021-1026. PubMed ID: 33517310
[TBL] [Abstract][Full Text] [Related]
2. Landscape of immune checkpoint inhibitor-related adverse events in Chinese population.
Li L; Li G; Rao B; Dong AH; Liang W; Zhu JX; Qin MP; Huang WW; Lu JM; Li ZF; Wu YZ
Sci Rep; 2020 Sep; 10(1):15567. PubMed ID: 32968172
[TBL] [Abstract][Full Text] [Related]
3. An Investigation of Nine Patients with Gastrointestinal Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors.
Miyahara K; Noda T; Ito Y; Hidaka H; Fujimoto S; Takedomi H; Akutagawa T; Sakata Y; Shimamura T; Tominaga N; Yamaguchi D; Fujimoto K
Digestion; 2020; 101(1):60-65. PubMed ID: 31801131
[TBL] [Abstract][Full Text] [Related]
4. Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors.
Rahma OE; Reuss JE; Giobbie-Hurder A; Shoja E Razavi G; Abu-Shawer O; Mehra P; Gupta S; Simon R; Khleif SN
Clin Cancer Res; 2021 Jan; 27(2):485-491. PubMed ID: 33082209
[TBL] [Abstract][Full Text] [Related]
5. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
[TBL] [Abstract][Full Text] [Related]
6. Medication-specific variations in morphological patterns of injury in immune check-point inhibitor-associated colitis.
Isidro RA; Ruan AB; Gannarapu S; Raj D; Rahma O; Grover S; Srivastava A
Histopathology; 2021 Mar; 78(4):532-541. PubMed ID: 32931028
[TBL] [Abstract][Full Text] [Related]
7. Haemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitors: a descriptive case study and literature review.
Dupré A; Michot JM; Schoeffler A; Frumholtz L; Baroudjian B; Delyon J; Lebbe C; Lambotte O
Br J Haematol; 2020 Jun; 189(5):985-992. PubMed ID: 32243578
[No Abstract] [Full Text] [Related]
8. Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study.
Okada N; Matsuoka R; Sakurada T; Goda M; Chuma M; Yagi K; Zamami Y; Nishioka Y; Ishizawa K
Sci Rep; 2020 Aug; 10(1):13773. PubMed ID: 32792640
[TBL] [Abstract][Full Text] [Related]
9. Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report.
Hultin S; Nahar K; Menzies AM; Long GV; Fernando SL; Atkinson V; Cebon J; Wong MG
BMC Nephrol; 2020 Sep; 21(1):391. PubMed ID: 32894101
[TBL] [Abstract][Full Text] [Related]
10. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
[TBL] [Abstract][Full Text] [Related]
11. Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis.
Sise ME; Wang Q; Seethapathy H; Moreno D; Harden D; Smith RN; Rosales IA; Colvin RB; Chute S; Cornell LD; Herrmann SM; Fadden R; Sullivan RJ; Yang NJ; Barmettler S; Wells S; Gupta S; Villani AC; Reynolds KL; Farmer J
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36657813
[TBL] [Abstract][Full Text] [Related]
12. Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma.
Vonderheid EC; Zhang Q; Lessin SR; Polansky M; Abrams JT; Bigler RD; Wasik MA
J Am Acad Dermatol; 1998 Feb; 38(2 Pt 1):207-20. PubMed ID: 9486676
[TBL] [Abstract][Full Text] [Related]
13. Elevated serum soluble interleukin-2 receptor levels increase malignancy-related risk in patients on chronic hemodialysis.
XiaoHong C; Bo S; FangFang X; Man G; JianZhou Z; ZhongHua L; WenLv L; XueSen C; XiaoQiang D; Boheng Z
Int J Clin Oncol; 2019 Sep; 24(9):1151-1160. PubMed ID: 31183777
[TBL] [Abstract][Full Text] [Related]
14. The significance of serum levels of soluble interleukin-2 receptor in patients undergoing maintenance hemodialysis.
Chen X; Li Y; Ding X; Zou J; Shen B; Liu Z; Lv W; Cao X; Xiang F
Ren Fail; 2020 Nov; 42(1):419-427. PubMed ID: 32401100
[No Abstract] [Full Text] [Related]
15. Elevation of soluble interleukin-2 receptor in patients with non-small cell lung cancer treated with gefitinib.
Kanazawa S; Yamaguchi K; Kinoshita Y; Komiyama Y; Muramatsu M; Nomura S
J Cancer Res Clin Oncol; 2006 Nov; 132(11):719-25. PubMed ID: 16835747
[TBL] [Abstract][Full Text] [Related]
16. Dynamics of clinical biomarkers as predictors of immunotherapy benefit in metastatic melanoma patients.
Hernando-Calvo A; García-Alvarez A; Villacampa G; Ortiz C; Bodet D; García-Patos V; Recio JA; Dienstmann R; Muñoz-Couselo E
Clin Transl Oncol; 2021 Feb; 23(2):311-317. PubMed ID: 32562197
[TBL] [Abstract][Full Text] [Related]
17. Serum level of a soluble receptor for interleukin-2 as a prognostic factor in patients with gastric cancer.
Saito H; Tsujitani S; Ikeguchi M; Maeta M; Kaibara N
Oncology; 1999 Apr; 56(3):253-8. PubMed ID: 10202282
[TBL] [Abstract][Full Text] [Related]
18. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N
BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab.
Oyanagi J; Koh Y; Sato K; Mori K; Teraoka S; Akamatsu H; Kanai K; Hayata A; Tokudome N; Akamatsu K; Nakanishi M; Ueda H; Yamamoto N
Lung Cancer; 2019 Jun; 132():107-113. PubMed ID: 31097082
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors in patients with solid tumors are not correlated.
Lissoni P; Rizzo V; Barni S; Rescaldani R; Rovelli F; Biondi A; Archili C; Frigerio F; Tancini G
Int J Biol Markers; 1989; 4(3):170-3. PubMed ID: 2614085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
